Table 1. Features of included studies.
| Features | Studies (n = 56) |
Patients (n = 20248) |
References |
|---|---|---|---|
| Year of publication, No. (%) | |||
| 2011–2012 | 7 (12.5) | 2499 (12.3) | (59–65) |
| 2013 | 8 (14.3) | 4471 (22.1) | (51–58) |
| 2014 | 21 (37.5) | 7216 (35.6) | (11–12, 32–50) |
| 2015 | 20 (35.7) | 6062 (29.9) | (7–10, 16–31) |
| Type of publication, No. (%) | |||
| Full paper | 45 (80.4) | 16511 (81.5) | (7–12, 16–38, 40–42, 44–49, 52, 54, 58, 61–64) |
| Abstract | 11 (19.6) | 3737 (18.5) | (39, 43, 50–51, 53, 55–57, 59–60, 65) |
| Study design, No. (%) | |||
| Prospective | 3 (5.4) | 801 (4.0) | (8, 22, 34) |
| Retrospective | 53 (64.6) | 19447 (96.0) | (7, 9–12, 16–21, 23–33, 35–65) |
| Type of cancer, No. (%) | |||
| Diffuse large B-cell lymphoma | 12 (25.5) | 4383 (25.2) | (33–34, 36, 38, 42, 45, 50–51, 54, 60, 63, 65) |
| Hodgkin's lymphoma | 7 (12.5) | 2799 (13.8) | (46, 53, 55, 57, 61–62, 64) |
| Colorectal carcinoma | 6 (10.7) | 1340 (6.6) | (8, 12, 17, 21–23) |
| Lung cancer | 4 (7.1) | 2085 (10.3) | (19, 40, 48–49) |
| Multiple sites | 3 (5.4) | 469 (2.3) | (31, 43, 56) |
| Urothelial carcinoma | 3 (5.4) | 374 (1.8) | (10, 16, 35) |
| Renal cell carcinoma | 3 (5.4) | 1549 (7.7) | (9, 30, 47) |
| Nasopharyngeal carcinoma | 3 (5.4) | 2475 (12.2) | (24, 41, 58) |
| Pancreatic cancer | 2 (3.4) | 795 (3.9) | (7, 20) |
| Esophageal carcinoma | 2 (3.4) | 566 (2.8) | (25–26) |
| Gastric cancer | 2 (3.4) | 815 (4.0) | (27, 32) |
| Burkitt lymphoma | 1 (1.2) | 62 (0. 3) | (18) |
| Endometrial cancer | 1 (1.2) | 605 (3.0) | (28) |
| Cervical cancer | 1 (1.2) | 485 (2.4) | (29) |
| Soft tissue sarcoma | 1 (1.2) | 340 (1.7) | (11) |
| Breast cancer | 1 (1.2) | 542 (2.7) | (37) |
| Hepatocellular carcinoma | 1 (1.2) | 210 (1.0) | (39) |
| Multiple myeloma | 1 (1.2) | 189 (0.9) | (52) |
| Melanoma | 1 (1.2) | 66 (0.3) | (59) |
| Follicular lymphoma | 1 (1.2) | 99 (0.5) | (44) |
| Cancer stage, No. (%) | |||
| Mixed | 37 (66.1) | 11583 (57.2) | (7, 11, 16, 18–20, 25, 27–28, 30–31, 33–36, 38–39, 42–46, 49–57, 60–65) |
| Non-metastatic | 12 (21.4) | 6742 (33.3) | (9–10, 12, 17, 23, 26, 29, 32, 37, 47–48, 58) |
| Metastatic | 7 (12.5) | 1923 (9.5) | (8, 21–22, 24, 40–41, 59) |
| Cutoff for LMR, No. (%) | |||
| 1.0 to < 2.0 | 8 (14.3) | 2607 (12.9) | (43, 50, 53, 55–57, 62, 65) |
| 2.0 to < 3.0 | 25 (44.6) | 7978 (39.4) | (7, 9–12, 16, 18, 22–26, 29, 31, 33, 35, 38, 45–46, 52, 54, 59–61, 63–64) |
| 3.0 to < 4.0 | 9 (16.1) | 3517 (17.4) | (8, 17, 19–21, 39, 42, 47–48) |
| ≥ 4.0 | 13 (23.2) | 5703 (28.2) | (27–28, 30, 32, 34, 37, 40–41, 44, 49, 51, 58) |
| Not reported | 1 (1.8) | 443 (2.2) | (36) |
| ROC curve, No. (%) | |||
| Considered | 44 (78.6) | 17497 (86.4) | (7–12, 18–19, 21–22, 24–29, 32–35, 37–42, 44–54, 58, 60–65) |
| Not considered | 12 (21.4) | 2751 (13.6) | (16–17, 20, 23, 30–31, 36, 43, 55–57, 59) |
| Reported outcome, No. (%) | |||
| Overall survival | 44 (78.7) | 14984 (72.0) | (8, 10–12, 16, 18–20, 22–24, 26–30, 32–36, 38–43, 45–49, 51–52, 54, 56–59, 61–65) |
| Cancer-specific survival | 11 (18.4) | 3972 (18.4) | (7–8, 11, 21–22, 25, 27–28, 47, 61–62) |
| Recurrence-free survival | 7 (12.2) | 1849 (7.7) | (12, 29, 32, 35, 38–39, 59) |
| Progression-free survival | 18 (34.0) | 5805 (32.6) | (18–19, 31, 34, 39, 42, 44–45, 49, 51, 53,55, 57, 60–63, 65) |
| Disease-free survival | 15 (26.5) | 6440 (34.2) | (8–9, 11, 17, 21, 23, 26–27, 31, 33, 37, 41, 46, 48, 50) |
Because of rounding, not all percentages total 100. LMR = lymphocyte to monocyte ratio.